SUBSCRIBE
SUBSCRIBE

23andMe

NEWS
Biotech Bay
Technology Will Human Beings Live Forever? These Companies Are Betting On It
May 16, 2016
 · 
1 min read
Biotech Bay
There’s A Big Problem With Tests Like The Ones 23andMe Offers
March 16, 2016
 · 
1 min read
Biotech Bay
Your DNA May Be To Blame Why You Are A Morning Person Or A Night Owl, 23andMe Study Reveals
February 3, 2016
 · 
1 min read
Pfizer and Allergan Execs Emphasize Joint Company’s Pipeline, Hint Job Cuts Will Be Minimal
Job Trends
23andMe CEO Shushed at J.P. Morgan, Reveals Company is Hiring for Drug-Development Lab in Bay Area
January 13, 2016
 · 
2 min read
Deals
23andMe CEO Talks About Company Comeback, Embattled Theranos
November 12, 2015
 · 
3 min read
Biotech Bay
23andMe Is Back On The Market -- Finally
November 6, 2015
 · 
1 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Biotech Pioneer’s Arivale, Banks $36 Million Series B, Trying to Pick Up Where 23andMe Left Off
July 14, 2015
 · 
3 min read
Biotech Bay
23andMe CEO Defends Practice Of Sharing Genetic Info With Pharma Companies
July 8, 2015
 · 
1 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Biotech Bay
23andMe Rakes in $79 Million As It Looks to Develop Own Drug Pipeline
July 7, 2015
 · 
4 min read
Load More
AWARDS
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Business
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
May 11, 2023
 · 
3 min read
Biotech Bay
23andMe Releases New Report Revealing Likelihood of Developing Lupus
May 9, 2023
 · 
6 min read
Business
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
May 8, 2023
 · 
5 min read
Business
23andMe Publishes Inaugural Environmental, Social and Governance Report
March 29, 2023
 · 
6 min read
Business
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
March 24, 2023
 · 
5 min read
Drug Development
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023
 · 
4 min read
Biotech Bay
23andMe to Present at Upcoming March 2023 Investor Conferences
February 22, 2023
 · 
3 min read
Business
23andMe Reports FY2023 Third Quarter Financial Results
February 8, 2023
 · 
22 min read
Business
23andMe to Report FY2023 Third Quarter Financial Results
January 26, 2023
 · 
3 min read
Business
23andMe Reports FY2023 Second Quarter Financial Results
November 7, 2022
 · 
21 min read
Load More